/

Società

La

Non verificato

Lantern Pharma

Di cosa scriviamo

BiotecnologiaEventiFarmaceuticaIndustriaOncologia

3 comunicati stampa

Guarda tutti i comunicati

07/08/2024

Oncologia

Salute

Medicina - Varie

Sanità

Farmaceutica

Biotecnologia

Eventi

Industria

Lantern Pharma Highlights Promising Preclinical Results of LP-184’s Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024

Fonte

Emittente

1.00

0

05/08/2024

Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort

Fonte

Emittente

1.00

0

10/07/2024

Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0